Maze Therapeutics opened lower at $36.29, compared with its previous close of $36.73. In the last trading session, the stock traded between $35.31 and $36.94. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in Maze Therapeutics is now worth
$ 226.01
Giving a profit of
$ 126.01 (126.01%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 9 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.68 (-1.86%)
Day High
$36.94
Day Low
$35.31
Day Open
$36.29
Prev Close
$36.73
Volume
3,79,546
1W Return
8.14%
1M Return
30.09%
3M Return
32.27%
6M Return
41.25%
1Y Return
11.74%
Fundamentals
Market Cap ($ Mn)
1,971
PE Ratio
-
PB Ratio
3.36
PEG Ratio
-
ROE
-67.07%
ROCE
-44.87%
EPS (TTM)
-
Investment Returns
1 Week
8.14%
1 Month
30.09%
3 Months
32.27%
6 Months
41.25%
9 Months
-23.66%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
11Nov
JP Morgan maintains Overweight on Maze Therapeutics, cuts target to $51
JP Morgan maintains an Overweight rating on Maze Therapeutics. Price target lowered from $53 to $51 by analyst Anupam Rama. Rating unchanged despite the reduction in valuation estimate.
Yesterday
10Nov
Maze Therapeutics Q3 Results: Loss widens to $0.79 per share
Maze Therapeutics reported a Q3 loss of $(0.79) per share. The result missed the analyst consensus of $(0.77) by 2.6%. Losses widened 19.7% YoY from $(0.66) per share in the prior year.
Canaccord Genuity initiated coverage on Maze Therapeutics. Analyst Whitney Ijem assigned a Buy rating to the stock. A price target of $75 was announced alongside the rating.
24 days ago
7Oct
Maze Therapeutics to present MZE829 and MZE782 data at ASN Kidney Week
Maze Therapeutics will present Phase 2 HORIZON trial data for MZE829 at ASN Kidney Week 2026. Two preclinical posters will highlight SLC6A19 inhibition via MZE782 for chronic kidney disease. Oral presentation scheduled for October 24, 2026, covering APOL1-mediated kidney disease outcomes. Preclinical research supports SLC6A19 inhibition as a complementary approach to SGLT2 inhibition.
1mo ago
24Sep
HC Wainwright reiterates Buy on Maze Therapeutics with $110 target
HC Wainwright & Co. reiterated a Buy rating on Maze Therapeutics. Analyst Ananda Ghosh maintained the price target at $110. The rating reaffirms confidence in the company's current trajectory.
1mo ago
14Aug
Maze Therapeutics appoints Johnson and Kornowski to board
Maze Therapeutics adds Paula Johnson and Sophie Kornowski to its board to support pipeline advancement. The company targets late 2026 or early 2027 for additional MZE829 data and 2027 for initial MZE782 data.
